Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732206 | 0.87 | S1PR1 (0.51) | S1PR1S1PR3HDAC4HDAC6KMT2A | |
| SCHEMBL3727505 | 0.86 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL3212083 | 0.81 | S1PR1 (0.50) | S1PR1S1PR3HDAC4HDAC6KMT2A | |
| SCHEMBL3728492 | 0.77 | S1PR1 (0.56) | S1PR1S1PR3 | |
| SCHEMBL14273124 | 0.76 | S1PR1 (0.43) | S1PR1S1PR3 | |
| SCHEMBL13424962 | 0.73 | S1PR1 (0.49) | S1PR1S1PR3KMT2AMEN1MAPT | |
| SCHEMBL3725961 | 0.73 | S1PR1 (0.89) | S1PR1S1PR3 | |
| SCHEMBL3730310 | 0.73 | S1PR1 (0.89) | S1PR1S1PR3 | |
| SCHEMBL3725965 | 0.73 | S1PR1 (0.89) | S1PR1S1PR3 | |
| SCHEMBL3730114 | 0.70 | S1PR1 (0.84) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069335-B1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2069335-B1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8288554-B2 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288554-B2 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288554-B2 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| CN-101522670-B | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-05-23 | — | — | CN | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| CN-101522670-A | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | CD4, FCGRT, CD47 | S1PR1 70/4885S1PR3 44/4885HDAC4 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.